{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T19:51:25Z","timestamp":1719085885009},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T00:00:00Z","timestamp":1411516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/2050-6511-15-52","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T11:01:07Z","timestamp":1411556467000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain"],"prefix":"10.1186","volume":"15","author":[{"given":"Helmut","family":"Ostermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon Andoni","family":"Barrueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"De Salas-Cansado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudie","family":"Charbonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,24]]},"reference":[{"key":"340_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1439-0507.2012.02193.x","volume":"55","author":"CT Rieger","year":"2012","unstructured":"Rieger CT, Cornely OA, Hoppe-Tichy T, Kiehl M, Knoth H, Thalheimer M, Schuler U, Ullmann AJ, Ehlken B, Ostermann H: Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. Mycoses. 2012, 55: 514-520. 10.1111\/j.1439-0507.2012.02193.x.","journal-title":"Mycoses"},{"key":"340_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3314\/jjmm.48.1","volume":"48","author":"DW Warnock","year":"2007","unstructured":"Warnock DW: Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi. 2007, 48: 1-12. 10.3314\/jjmm.48.1.","journal-title":"Nippon Ishinkin Gakkai Zasshi"},{"key":"340_CR3","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002, 100: 4358-4366. 10.1182\/blood-2002-05-1496.","journal-title":"Blood"},{"key":"340_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/318483","volume":"32","author":"SJ Lin","year":"2001","unstructured":"Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001, 32: 358-366. 10.1086\/318483.","journal-title":"Clin Infect Dis"},{"key":"340_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","volume":"5","author":"LS Wilson","year":"2002","unstructured":"Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J: The direct cost and incidence of systemic fungal infections. Value Health. 2002, 5: 26-34. 10.1046\/j.1524-4733.2002.51108.x.","journal-title":"Value Health"},{"key":"340_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1086\/502581","volume":"26","author":"J Morgan","year":"2005","unstructured":"Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM: Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol. 2005, 26: 540-547. 10.1086\/502581.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"340_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/496922","volume":"41","author":"TE Zaoutis","year":"2005","unstructured":"Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005, 41: 1232-1239. 10.1086\/496922.","journal-title":"Clin Infect Dis"},{"key":"340_CR8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2146\/ajhp080325","volume":"66","author":"J Menzin","year":"2009","unstructured":"Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G: Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009, 66: 1711-1717. 10.2146\/ajhp080325.","journal-title":"Am J Health Syst Pharm"},{"key":"340_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1517\/14656561003649555","volume":"11","author":"C Rubio-Terr\u00e9s","year":"2010","unstructured":"Rubio-Terr\u00e9s C, Grau S: Pharmacoeconomics of voriconazole. Expert Opin Pharmacother. 2010, 11: 877-887. 10.1517\/14656561003649555.","journal-title":"Expert Opin Pharmacother"},{"key":"340_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/annonc\/mdr407","volume":"23","author":"M Ruhnke","year":"2012","unstructured":"Ruhnke M, B\u00f6hme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horger M, Hof H, Karthaus M, Kr\u00fcger W, Maschmeyer G, Penack O, Ritter J, Schwartz S: Diagnosis of invasive fungal infections in hematology and oncology\u2013guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol. 2012, 23: 823-833. 10.1093\/annonc\/mdr407.","journal-title":"Ann Oncol"},{"key":"340_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","volume":"93","author":"S Mousset","year":"2014","unstructured":"Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Kr\u00fcger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Sudhoff T, Ullmann AJ, Wolf HH, Maschmeyer G, B\u00f6hme A: Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014, 93: 13-32. 10.1007\/s00277-013-1867-1.","journal-title":"Ann Hematol"},{"key":"340_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bmt.2010.175","volume":"46","author":"J Maertens","year":"2011","unstructured":"Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fl\u00fcckiger U, Fr\u00eare P, Gachot B, Heinz WJ, Lass-Fl\u00f6rl C, Ribaud P, Thiebaut A, Cordonnier C: European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update. Bone Marrow Transplant. 2011, 46: 709-718. 10.1038\/bmt.2010.175.","journal-title":"Bone Marrow Transplant"},{"key":"340_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.eimc.2011.01.010","volume":"29","author":"J Fort\u00fan","year":"2011","unstructured":"Fort\u00fan J, Carratal\u00e1 J, Gavald\u00e1 J, Lizasoain M, Salavert M, de la C\u00e1mara R, Borges M, Cervera C, Garnacho J, Lassaleta \u00c1, Lumbreras C, Sanz M\u00c1, Ramos JT, Torre-Cisneros J, Aguado JM, Cuenca-Estrella M: Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update. Enferm Infecc Microbiol Clin. 2011, 29: 435-454. 10.1016\/j.eimc.2011.01.010.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"340_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002, 347: 408-415. 10.1056\/NEJMoa020191.","journal-title":"N Engl J Med"},{"key":"340_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007, 44: 1289-1297. 10.1086\/514341.","journal-title":"Clin Infect Dis"},{"key":"340_CR16","volume-title":"Hospital database analysis of haematologic malignancy and bone marrow transplant\/stem cell transplant (BMT\/SCT) patients with invasive aspergillosis (IA)","author":"JM Stephens","year":"2010","unstructured":"Stephens JM, Gao X, Ji X, Baddley J, Schlamm H, Tarallo M: Hospital database analysis of haematologic malignancy and bone marrow transplant\/stem cell transplant (BMT\/SCT) patients with invasive aspergillosis (IA). 2010, Vancouver, BC, Canada: Poster presented at the 48th IDSA Annual Meeting"},{"key":"340_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","volume":"277","author":"DW Bates","year":"1997","unstructured":"Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997, 277: 307-311. 10.1001\/jama.1997.03540280045032.","journal-title":"JAMA"},{"key":"340_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1524-4733.2006.00076.x","volume":"9","author":"JP Jansen","year":"2006","unstructured":"Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A: Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health. 2006, 9: 12-23. 10.1111\/j.1524-4733.2006.00076.x.","journal-title":"Value Health"},{"key":"340_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10198-008-0104-7","volume":"10","author":"D Sch\u00fcrmann","year":"2009","unstructured":"Sch\u00fcrmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A: Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ. 2009, 10: 65-79. 10.1007\/s10198-008-0104-7.","journal-title":"Eur J Health Econ"},{"key":"340_CR20","unstructured":"Oblikue Consulting: E-Salud. Spanish Cost Database. Available at: http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"340_CR21","unstructured":"Lauer Taxe: Pharmindex for Germany drug cost. Available at: http:\/\/www.lauer-fischer.de\/lf\/Seiten\/WEBAPO-Lauer-Taxe\/WEBAPO-Lauer-Taxe-demo.aspx"},{"key":"340_CR22","unstructured":"General Council of Official Colleges of Pharmacists: Bot Plus database. Available at: https:\/\/botplusweb.portalfarma.com"},{"key":"340_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1399-3062.2007.00210.x","volume":"9","author":"JR Wingard","year":"2007","unstructured":"Wingard JR, Herbrecht R, Mauskopf J, Schlamm HT, Marciniak A, Roberts CS: Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis. 2007, 9: 182-188. 10.1111\/j.1399-3062.2007.00210.x.","journal-title":"Transpl Infect Dis"},{"key":"340_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/jac\/dkh535","volume":"55","author":"R Wenzel","year":"2005","unstructured":"Wenzel R, Del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, Morris S, Schlamm H, Troke P, Marciniak A: Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother. 2005, 55: 352-361. 10.1093\/jac\/dkh535.","journal-title":"J Antimicrob Chemother"},{"key":"340_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1600-0609.2004.00273.x","volume":"73","author":"E Jantunen","year":"2004","unstructured":"Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T, Kuittinen O, Lepp\u00e4 S, Anttila VJ, It\u00e4l\u00e4 M, Wiklund T, Remes K, Nousiainen T: Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol. 2004, 73: 174-178. 10.1111\/j.1600-0609.2004.00273.x.","journal-title":"Eur J Haematol"},{"key":"340_CR26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1155\/2004\/183087","volume":"15","author":"C Rotstein","year":"2004","unstructured":"Rotstein C, Laverdi\u00e8re M, Marciniak A, Ali F: An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can J Infect Dis Med Microbiol. 2004, 15: 277-284.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"340_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2710.2009.01070.x","volume":"35","author":"D Capone","year":"2010","unstructured":"Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M, Nappi R, Ciotola A, D\u2019Alessandro V, Renda A, Basile V, Federico S: Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther. 2010, 35: 121-124. 10.1111\/j.1365-2710.2009.01070.x.","journal-title":"J Clin Pharm Ther"},{"key":"340_CR28","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1592\/phco.30.8.842","volume":"30","author":"E Dodds-Ashley","year":"2010","unstructured":"Dodds-Ashley E: Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010, 30: 842-854. 10.1592\/phco.30.8.842.","journal-title":"Pharmacotherapy"},{"key":"340_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/138920011795101868","volume":"12","author":"M Pieri","year":"2011","unstructured":"Pieri M, Miraglia N, Polichetti G, Tarantino G, Acampora A, Capone D: Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. Curr Drug Metab. 2011, 12: 253-267. 10.2174\/138920011795101868.","journal-title":"Curr Drug Metab"},{"key":"340_CR30","unstructured":"Pfizer Inc: Vfend full prescribing information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021266s032lbl.pdf"},{"key":"340_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1086\/343746","volume":"35","author":"BA Potoski","year":"2002","unstructured":"Potoski BA, Brown J: The safety of voriconazole. Clin Infect Dis. 2002, 35: 1273-1275. 10.1086\/343746.","journal-title":"Clin Infect Dis"},{"key":"340_CR32","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3748\/wjg.15.2817","volume":"15","author":"G Tarantino","year":"2009","unstructured":"Tarantino G, Di Minno MN, Capone D: Drug-induced liver injury: is it somehow foreseeable?. World J Gastroenterol. 2009, 15: 2817-2833. 10.3748\/wjg.15.2817.","journal-title":"World J Gastroenterol"},{"key":"340_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","volume":"69","author":"MD Moen","year":"2009","unstructured":"Moen MD, Lyseng-Williamson KA, Scott LJ: Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009, 69: 361-392. 10.2165\/00003495-200969030-00010.","journal-title":"Drugs"},{"key":"340_CR34","unstructured":"Gilead Sciences Ltd: Summary of Product Characteristics: Ambisome. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/1236\/SPC\/ambisome\/"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-15-52.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-15-52\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-15-52","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-15-52.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T05:58:24Z","timestamp":1630562304000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-15-52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,24]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-15-52","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,24]]},"assertion":[{"value":"2 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"52"}}